ClinicalTrials.gg
CompletedNCT06612879Updated Apr 22, 2025

A Study to Find Out How BIIB141 (Omaveloxolone) Moves From the Blood Into the Breastmilk of Healthy Women Who Are Breastfeeding or Pumping Milk

A Phase 1 interventional study of Omaveloxolone in Healthy Volunteer, sponsored by Biogen. Completed at 1 site in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-22.

Sponsored by Biogen · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2025, 1 year 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

In this study, researchers will learn how BIIB141, also known as omaveloxolone or SKYCLARYS®, moves through the body. This is a drug available for doctors to prescribe for patients with Friedrich's Ataxia. But, this drug has not yet been tested in women who have recently given birth and are breastfeeding or pumping milk for their babies. So, researchers do not know how much of the drug could be passed on to babies through the breastmilk of mothers who may take BIIB141.

The main objective of this study is to learn how a single dose of BIIB141 is processed in both the breastmilk and in the blood of healthy women who are breastfeeding.

The main question researchers want to answer in this study is:

  • How does BIIB141 move from the blood into the breastmilk?

Researchers will also learn more about:

  • How BIIB141 moves through the blood
  • What dose of BIIB141 a baby may get from the mother's breastmilk
  • Any medical problems the participants have during the study

This study will be done as follows:

  • Participants will be screened to check if they can join the study. The screening period will be up to 28 days, after which participants will check into their study research center.
  • Participants will take a single dose of BIIB141 as a tablet by mouth on Day 1.
  • Participants will remain at their study research center for 6 days. During this time, the participants will be provided with an electric breast pump. This is so that the researchers can collect breastmilk samples before and after the participants take BIIB141. The researchers will also collect blood samples.
  • After leaving the study research center, the participants will return every 2 days for the next 10 days for more tests and checkups.
  • Finally, there will be a follow-up with a "lactation consultant" up to 30 days after each participant's last study visit. This is someone who can help participants with breastfeeding or pumping.
  • Each participant will be in the study for up to 2.5 months.
02

Conditions studied

  • Healthy Volunteer
03

In context

Lead sponsor

Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.

Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Lactating female 18 to 45 years of age.
  • Has given birth to an infant of at least 37 weeks' gestation.
  • Is at least 6 weeks postpartum by Day 1.
  • at screening between 18.0 and and \< 35.0 kilograms per meter square (kg/m\^2), inclusive.
  • Is willing to discontinue breastfeeding their infant from check-in (Day -1) through 19 days after dosing.
  • Has never taken omaveloxolone.

Key Exclusion Criteria:

  • History of any cardiovascular, endocrine, gastrointestinal, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, dermatologic, neurologic, psychiatric, or renal disease, or other major disease, as determined by the Investigator.
  • Clinically significant (as determined by the Investigator) 12-lead (ECG) abnormalities.
  • History of, or positive test result at Screening for, .
  • Chronic, recurrent, or serious infection (e.g., pneumonia, septicemia), as determined by the Investigator, within 90 days prior to Screening or between Screening and Day -1.
  • Presence or history of hypotension or hypertension.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Omaveloxolone

    Participants will receive a single oral dose of omaveloxolone on Day 1.

    Drug: Omaveloxolone

Interventions

  • Administered as specified in the treatment arm.

    Also known as: BIIB141, SKYCLARYS

06

What researchers measure

Primary outcomes

  1. Maximum Observed Concentration (Cmax) of Omaveloxolone in Breast Milk

    Time frame: Predose and at multiple timepoints postdose (up to Day 15)

  2. Time to Achieve Cmax (Tmax) of Omaveloxolone in Breast Milk

    Time frame: Predose and at multiple timepoints postdose (up to Day 15)

  3. Average Concentration Based on Area Under the Concentration-Time Curve (AUC [Cav]) of Omaveloxolone in Breast Milk

    Time frame: Predose and at multiple timepoints postdose (up to Day 15)

  4. Area Under the Concentration Time Curve From Time Zero to the Time of Last Measurable Concentration (AUC0-tlast) of Omaveloxolone in Breast Milk

    Time frame: Predose and at multiple timepoints postdose (up to Day 15)

  5. Time of the Last Measurable Concentration (Tlast) of Omaveloxolone in Breast milk

    Time frame: Predose and at multiple timepoints postdose (up to Day 15)

  6. AUC Time Curve From Time Zero to Infinity (AUCinf) of Omaveloxolone in Breast Milk

    Time frame: Predose and at multiple timepoints postdose (up to Day 15)

  7. Milk-to-Plasma Ratio (M/P) of Omaveloxolone

    Time frame: Predose and at multiple timepoints postdose (up to Day 15)

  8. Cumulative Amount of Omaveloxolone Excreted in Breast Milk (Ae) Over 24 Hours (Ae0-24) Postdose

    Time frame: At multiple timepoints postdose (up to 24 hours)

  9. Cumulative Amount of Omaveloxolone Excreted in Breast Milk (Ae) Over 96 Hours (Ae0-96) Postdose

    Time frame: At multiple timepoints postdose (up to 96 hours)

  10. Fraction of Omaveloxolone Excreted in Breast Milk (Fe) Over 24 Hours (Fe0-24)

    Time frame: At multiple timepoints postdose (up to 24 hours)

  11. Fraction of Omaveloxolone Excreted in Breast Milk (Fe) Over 96 Hours (Fe0-96)

    Time frame: At multiple timepoints postdose (up to 96 hours)

Secondary outcomes

  1. Cmax of Omaveloxolone in Plasma

    Time frame: Predose and at multiple timepoints postdose (up to Day 15)

  2. Tmax of Omaveloxolone in Plasma

    Time frame: Predose and at multiple timepoints postdose (up to Day 15)

  3. AUC[Cav] of Omaveloxolone in Plasma

    Time frame: Predose and at multiple timepoints postdose (up to Day 15)

  4. AUC0-tlast of Omaveloxolone in Plasma

    Time frame: Predose and at multiple timepoints postdose (up to Day 15)

  5. AUCinf of Omaveloxolone in Plasma

    Time frame: Predose and at multiple timepoints postdose (up to Day 15)

  6. Terminal Elimination Rate Constant (λz) of Omaveloxolone in Plasma

    Time frame: Predose and at multiple timepoints postdose (up to Day 15)

  7. Apparent Plasma Terminal Elimination Half-Life (t1/2) of Omaveloxolone

    Time frame: Predose and at multiple timepoints postdose (up to Day 15)

  8. Apparent Plasma Clearance After Extravascular Administration (CL/F) of Omaveloxolone

    Time frame: Predose and at multiple timepoints postdose (up to Day 15)

  9. Apparent Volume of Distribution During the Terminal Elimination Phase After Extravascular Administration (Vz/F) of Omaveloxolone

    Time frame: Predose and at multiple timepoints postdose (up to Day 15)

  10. Percent of Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC%extrap) of Omaveloxolone

    Time frame: Predose and at multiple timepoints postdose (up to Day 15)

  11. Plasma Unbound Fraction (fu,p) of Omaveloxolone

    Time frame: Predose and at multiple timepoints postdose (up to Day 15)

  12. Cmax of Unbound Plasma Fraction (Cmax,u) of Omaveloxolone

    Time frame: Predose and at multiple timepoints postdose (up to Day 15)

  13. Cav of Unbound Plasma Fraction (AUCinf,u) of Omaveloxolone

    Time frame: Predose and at multiple timepoints postdose (up to Day 15)

  14. AUC0-tlast of Unbound Plasma Fraction (AUC0-last,u) of Omaveloxolone in Plasma

    Time frame: Predose and at multiple timepoints postdose (up to Day 15)

  15. AUCinf of Unbound Plasma Fraction (AUCinf,u) of Omaveloxolone

    Time frame: Predose and at multiple timepoints postdose (up to Day 15)

  16. Estimated Daily Infant Dosage (DID) of Omaveloxolone

    Time frame: Predose and at multiple timepoints postdose (up to Day 15)

  17. Relative Infant Dose (RID) of Omaveloxolone

    Time frame: Predose and at multiple timepoints postdose (up to Day 15)

  18. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From Day 1 up to end of study follow-up (up to 45 days)

07

Study locations

1 site
  • Fortrea Madison WI, CRU
    Madison, Wisconsin 53704, United States
08

References and documents

Individual participant data

Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2024 to primary completion in Mar 2025, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2024
First posted
Sep 25, 2024
StartActual
Oct 18, 2024
Primary completionActual
Mar 11, 2025
CompletionActual
Apr 8, 2025
Last update
Apr 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06612879
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Sep 25, 2024
Start date
Oct 18, 2024
Primary completion
Mar 11, 2025
Completion
Apr 8, 2025
Last update
Apr 22, 2025

Study contacts

Medical Director
study director · Biogen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Omaveloxolone

Start the discussion